Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis

Sakiko Tsugawa, Yoshihiro Noda, Ryosuke Tarumi, Yu Mimura, Kazunari Yoshida, Yusuke Iwata, Muhammad Elsalhy, Minori Kuromiya, Shin Kurose, Fumi Masuda, Shinji Morita, Kamiyu Ogyu, Eric Plitman, Masataka Wada, Takahiro Miyazaki, Ariel Graff-Guerrero, Masaru Mimura, Shinichiro Nakajima

Research output: Contribution to journalReview article

Abstract

Background: Glutathione is among the important antioxidants to prevent oxidative stress. However, the relationships between abnormality in the glutathione system and pathophysiology of schizophrenia remain uncertain due to inconsistent findings on glutathione levels and/or glutathione-related enzyme activities in patients with schizophrenia. Methods: A systematic literature search was conducted using Embase, Medline, PsycINFO, and PubMed. Original studies, in which three metabolite levels (glutathione, glutathione disulfide, and total glutathione (glutathione+glutathione disulfide)) and five enzyme activities (glutathione peroxidase, glutathione reductase, glutamate-cysteine ligase, glutathione synthetase, and glutathione S-transferase) were measured with any techniques in both patients with schizophrenia and healthy controls, were included. Standardized mean differences were calculated to determine the group differences in the glutathione levels with a random-effects model. Results: We identified 41, 9, 15, 38, and seven studies which examined glutathione, glutathione disulfide, total glutathione, glutathione peroxidase, and glutathione reductase, respectively. Patients with schizophrenia had lower levels of both glutathione and total glutathione and decreased activity of glutathione peroxidase compared to controls. Glutathione levels were lower in unmedicated patients with schizophrenia than those in controls while glutathione levels did not differ between patients with first-episode psychosis and controls. Conclusions: Our findings suggested that there may be glutathione deficits and abnormalities in the glutathione redox cycle in patients with schizophrenia. However, given the small number of studies examined the entire glutathione system, further studies are needed to elucidate a better understanding of disrupted glutathione function in schizophrenia, which may pave the way for the development of novel therapeutic strategies in this disorder.

Original languageEnglish
JournalJournal of Psychopharmacology
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Glutathione
Meta-Analysis
Schizophrenia
Enzymes
Glutathione Peroxidase
Glutathione Disulfide
Glutathione Reductase
Glutathione Synthase
Glutamate-Cysteine Ligase
Glutathione Transferase
PubMed
Psychotic Disorders
Oxidation-Reduction
Oxidative Stress

Keywords

  • glutathione
  • oxidative stress
  • redox dysregulation
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia : A systematic review and meta-analysis. / Tsugawa, Sakiko; Noda, Yoshihiro; Tarumi, Ryosuke; Mimura, Yu; Yoshida, Kazunari; Iwata, Yusuke; Elsalhy, Muhammad; Kuromiya, Minori; Kurose, Shin; Masuda, Fumi; Morita, Shinji; Ogyu, Kamiyu; Plitman, Eric; Wada, Masataka; Miyazaki, Takahiro; Graff-Guerrero, Ariel; Mimura, Masaru; Nakajima, Shinichiro.

In: Journal of Psychopharmacology, 01.01.2019.

Research output: Contribution to journalReview article

Tsugawa, S, Noda, Y, Tarumi, R, Mimura, Y, Yoshida, K, Iwata, Y, Elsalhy, M, Kuromiya, M, Kurose, S, Masuda, F, Morita, S, Ogyu, K, Plitman, E, Wada, M, Miyazaki, T, Graff-Guerrero, A, Mimura, M & Nakajima, S 2019, 'Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis', Journal of Psychopharmacology. https://doi.org/10.1177/0269881119845820
Tsugawa, Sakiko ; Noda, Yoshihiro ; Tarumi, Ryosuke ; Mimura, Yu ; Yoshida, Kazunari ; Iwata, Yusuke ; Elsalhy, Muhammad ; Kuromiya, Minori ; Kurose, Shin ; Masuda, Fumi ; Morita, Shinji ; Ogyu, Kamiyu ; Plitman, Eric ; Wada, Masataka ; Miyazaki, Takahiro ; Graff-Guerrero, Ariel ; Mimura, Masaru ; Nakajima, Shinichiro. / Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia : A systematic review and meta-analysis. In: Journal of Psychopharmacology. 2019.
@article{ca3d8872842e41b199eb3f6da44a8a12,
title = "Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis",
abstract = "Background: Glutathione is among the important antioxidants to prevent oxidative stress. However, the relationships between abnormality in the glutathione system and pathophysiology of schizophrenia remain uncertain due to inconsistent findings on glutathione levels and/or glutathione-related enzyme activities in patients with schizophrenia. Methods: A systematic literature search was conducted using Embase, Medline, PsycINFO, and PubMed. Original studies, in which three metabolite levels (glutathione, glutathione disulfide, and total glutathione (glutathione+glutathione disulfide)) and five enzyme activities (glutathione peroxidase, glutathione reductase, glutamate-cysteine ligase, glutathione synthetase, and glutathione S-transferase) were measured with any techniques in both patients with schizophrenia and healthy controls, were included. Standardized mean differences were calculated to determine the group differences in the glutathione levels with a random-effects model. Results: We identified 41, 9, 15, 38, and seven studies which examined glutathione, glutathione disulfide, total glutathione, glutathione peroxidase, and glutathione reductase, respectively. Patients with schizophrenia had lower levels of both glutathione and total glutathione and decreased activity of glutathione peroxidase compared to controls. Glutathione levels were lower in unmedicated patients with schizophrenia than those in controls while glutathione levels did not differ between patients with first-episode psychosis and controls. Conclusions: Our findings suggested that there may be glutathione deficits and abnormalities in the glutathione redox cycle in patients with schizophrenia. However, given the small number of studies examined the entire glutathione system, further studies are needed to elucidate a better understanding of disrupted glutathione function in schizophrenia, which may pave the way for the development of novel therapeutic strategies in this disorder.",
keywords = "glutathione, oxidative stress, redox dysregulation, Schizophrenia",
author = "Sakiko Tsugawa and Yoshihiro Noda and Ryosuke Tarumi and Yu Mimura and Kazunari Yoshida and Yusuke Iwata and Muhammad Elsalhy and Minori Kuromiya and Shin Kurose and Fumi Masuda and Shinji Morita and Kamiyu Ogyu and Eric Plitman and Masataka Wada and Takahiro Miyazaki and Ariel Graff-Guerrero and Masaru Mimura and Shinichiro Nakajima",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/0269881119845820",
language = "English",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia

T2 - A systematic review and meta-analysis

AU - Tsugawa, Sakiko

AU - Noda, Yoshihiro

AU - Tarumi, Ryosuke

AU - Mimura, Yu

AU - Yoshida, Kazunari

AU - Iwata, Yusuke

AU - Elsalhy, Muhammad

AU - Kuromiya, Minori

AU - Kurose, Shin

AU - Masuda, Fumi

AU - Morita, Shinji

AU - Ogyu, Kamiyu

AU - Plitman, Eric

AU - Wada, Masataka

AU - Miyazaki, Takahiro

AU - Graff-Guerrero, Ariel

AU - Mimura, Masaru

AU - Nakajima, Shinichiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Glutathione is among the important antioxidants to prevent oxidative stress. However, the relationships between abnormality in the glutathione system and pathophysiology of schizophrenia remain uncertain due to inconsistent findings on glutathione levels and/or glutathione-related enzyme activities in patients with schizophrenia. Methods: A systematic literature search was conducted using Embase, Medline, PsycINFO, and PubMed. Original studies, in which three metabolite levels (glutathione, glutathione disulfide, and total glutathione (glutathione+glutathione disulfide)) and five enzyme activities (glutathione peroxidase, glutathione reductase, glutamate-cysteine ligase, glutathione synthetase, and glutathione S-transferase) were measured with any techniques in both patients with schizophrenia and healthy controls, were included. Standardized mean differences were calculated to determine the group differences in the glutathione levels with a random-effects model. Results: We identified 41, 9, 15, 38, and seven studies which examined glutathione, glutathione disulfide, total glutathione, glutathione peroxidase, and glutathione reductase, respectively. Patients with schizophrenia had lower levels of both glutathione and total glutathione and decreased activity of glutathione peroxidase compared to controls. Glutathione levels were lower in unmedicated patients with schizophrenia than those in controls while glutathione levels did not differ between patients with first-episode psychosis and controls. Conclusions: Our findings suggested that there may be glutathione deficits and abnormalities in the glutathione redox cycle in patients with schizophrenia. However, given the small number of studies examined the entire glutathione system, further studies are needed to elucidate a better understanding of disrupted glutathione function in schizophrenia, which may pave the way for the development of novel therapeutic strategies in this disorder.

AB - Background: Glutathione is among the important antioxidants to prevent oxidative stress. However, the relationships between abnormality in the glutathione system and pathophysiology of schizophrenia remain uncertain due to inconsistent findings on glutathione levels and/or glutathione-related enzyme activities in patients with schizophrenia. Methods: A systematic literature search was conducted using Embase, Medline, PsycINFO, and PubMed. Original studies, in which three metabolite levels (glutathione, glutathione disulfide, and total glutathione (glutathione+glutathione disulfide)) and five enzyme activities (glutathione peroxidase, glutathione reductase, glutamate-cysteine ligase, glutathione synthetase, and glutathione S-transferase) were measured with any techniques in both patients with schizophrenia and healthy controls, were included. Standardized mean differences were calculated to determine the group differences in the glutathione levels with a random-effects model. Results: We identified 41, 9, 15, 38, and seven studies which examined glutathione, glutathione disulfide, total glutathione, glutathione peroxidase, and glutathione reductase, respectively. Patients with schizophrenia had lower levels of both glutathione and total glutathione and decreased activity of glutathione peroxidase compared to controls. Glutathione levels were lower in unmedicated patients with schizophrenia than those in controls while glutathione levels did not differ between patients with first-episode psychosis and controls. Conclusions: Our findings suggested that there may be glutathione deficits and abnormalities in the glutathione redox cycle in patients with schizophrenia. However, given the small number of studies examined the entire glutathione system, further studies are needed to elucidate a better understanding of disrupted glutathione function in schizophrenia, which may pave the way for the development of novel therapeutic strategies in this disorder.

KW - glutathione

KW - oxidative stress

KW - redox dysregulation

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85065421008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065421008&partnerID=8YFLogxK

U2 - 10.1177/0269881119845820

DO - 10.1177/0269881119845820

M3 - Review article

AN - SCOPUS:85065421008

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

ER -